



(51) International Patent Classification:
C07D 233/56 (2006.01) C07D 409/14 (2006.01)
C07D 409/02 (2006.01) A61K 31/381 (2006.01)
C07D 409/04 (2006.01) A61K 31/4436 (2006.01)
C07D 409/10 (2006.01) A61P 3/00 (2006.01)
C07D 409/12 (2006.01)

(21) International Application Number: PCT/US2015/054581

(22) International Filing Date: 8 October 2015 (08.10.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/061,330 8 October 2014 (08.10.2014) US

(71) Applicant: JANSSEN PHARMACEUTICA NV
[BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors: KUO, Gee-Hong; Welsh & McKean Roads, Spring House, Pennsylvania 19477 (US). PLAYER, Mark R.; Welsh & McKean Roads, Spring House, Pennsylvania 19477 (US). YANG, Shyh-Ming; 4895 Redfield Road, Doylestown, Pennsylvania 18902 (US). ZHANG, Yue-Mie; Welsh & McKean Roads, Spring House, Pennsylvania 19477 (US). HUANG, Hui; Welsh & McLean Roads, Spring House, Pennsylvania 19477 (US).

(74) Agents: PLANTZ, Bernard F. et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES



(I)

(57) Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) wherein R₁, R₂, R₃, R₅, R₆, W, and A are defined herein.

WO 2016/057731 A1